PRISM BioLab will utilize PepMetics®, innovative
small molecules that mimic three-dimensional structures
of alpha-helix and beta-turns of peptides for drug
discovery against oncology target selected by Ono
TOKYO, April 25,
2024 /PRNewswire/ -- PRISM BioLab, Co. Ltd.
("PRISM"), a leading discovery and development biotechnology
company designing small molecule inhibitors of protein-protein
interaction (PPI) targets, today announced that it has entered into
a target-exclusive research and licensing agreement with ONO
PHARMACEUTICAL CO., LTD. ("Ono ").
Under the terms of the agreement, Ono and PRISM
will jointly create a development candidate for Ono's oncology
target using PepMetics® technology. Upon
identification of the development candidate, PRISM will license its
rights to Ono for clinical development and commercialization. The
deal includes upfront payments, pre-clinical, clinical and
commercialization success-based milestones, royalties on
future net sales, and other terms. Specific financial terms are not
disclosed.
"We highly appreciate PRISM's PepMetics® technology
in PPI drug discovery", said Seishi
Katsumata, Executive Director, Discovery & Research of
Ono. "Through this drug discovery collaboration, we are excited to
work with PRISM to identify and develop novel small molecule drugs
for therapeutic targets that had been previously difficult to
modulate with a small molecule, leading to further expansion of our
development pipeline to address unmet medical needs across a broad
range of diseases."
"We are very excited to enter into this collaboration with Ono
who has a history of creating innovative drugs. ", said
Dai Takehara, President & CEO of
PRISM Biolab. "We believe that our PepMetics® technology
will change the current paradigm in drug discovery by turning
previously undruggable PPIs into targets readily druggable with
small molecules. Through close collaboration between creative
scientists of both companies, we expect to generate innovative and
game-changing drugs for the benefit of patients."
About Ono Pharmaceutical Co., Ltd.
Ono Pharmaceutical Co., Ltd., headquartered in Osaka, is an R&D-oriented pharmaceutical
company committed to creating innovative medicines in specific
areas. ONO focuses its research on the oncology, immunology,
neurology and specialty research with high medical needs as
priority areas for discovery and development of innovative
medicines. For further information, please visit the company's
website at https://www.ono-pharma.com/.
About PRISM BioLab
PRISM BioLab is a discovery and development biotechnology
company utilizing proprietary PepMetics® technology to
discover orally available small molecule inhibitors of
protein-protein interaction (PPI) targets and transform lives of
patients suffering from cancer, autoimmune, fibrosis and other
diseases. PepMetics® are a unique class of small
molecules that mimic three-dimensional structures of alpha-helix
and beta-turn, the peptide structures commonly found in
intracellular PPI interphases and receptor-ligand interactions. By
combining proprietary chemistry, know-how around PPI targets and
AI-supported design, PepMetics® technology can deliver
inhibitors of challenging PPI targets. The technology holds promise
to expand the field of drug discovery by turning previously
undruggable PPIs into targets readily druggable with small
molecules and by generating oral small molecule alternatives for
injectable biologics.
PRISM BioLab is collaborating on new PPI targets with global and
Japanese pharmaceutical companies. PepMetics® targeting
CBP/beta-catenin PPIs licensed to Eisai Co., Ltd. and Ohara
Pharmaceuticals Co., Ltd. are in clinical development for cancer
and liver disease, respectively.
www.prismbiolab.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/prism-biolab-enters-into-a-joint-research-and-licensing-agreement-with-ono-302124401.html
SOURCE PRISM BioLab Co., Ltd.